Journey Clinical is a pioneering company committed to revolutionizing the mental health landscape through the promotion of innovative treatments, particularly focusing on Psychedelic-Assisted Psychotherapy, with an initial emphasis on Ketamine-Assisted Psychotherapy (KAP). The company has created a robust health-tech platform designed to improve access to these transformative therapies, while its collaborative care model integrates licensed psychotherapists with an in-house medical team to ensure tailored treatment planning and effective monitoring. Recently, Journey Clinical successfully secured a Series A funding round led by Union Square Ventures, further supported by a group of esteemed investors. The organization prides itself on fostering an inclusive and mission-driven workplace that not only encourages professional growth and collaboration but is also dedicated to enhancing clinical outcomes and patient care, ultimately aiming to make a profound impact on mental health care and the lives of those it serves.